Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Video game therapy shows promise for kids with ADHD

NCT ID NCT07173439

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 26, 2026 · Last updated Jun 26, 2026

Summary

This study tested a digital therapeutic device that combines driving simulations and memory exercises to improve attention and reduce hyperactivity in children with ADHD. About 120 children aged 6 to 12 took part, with some using the active device and others a placebo version. The goal was to see if this non-drug approach could safely ease core ADHD symptoms.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
digital therapeutic device (driving simulation and N-Back cognitive training)
What this could lead to
If it works, this could offer a drug-free option to help children with ADHD improve attention and reduce hyperactivity.
What could go wrong
This is a single completed trial with 120 participants, so results may not apply to all children. The placebo also included a driving simulation, which may reduce the apparent benefit.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

120 people

The number who actually took part.

Started

Apr 2024

Finished

May 2025

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

6 to 12 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Subjects must meet all the following inclusion criteria: * Children and adolescents aged 6 years or older but under 13 years, both male and female. * Diagnosed with ADHD according to DSM-5 criteria or ICD-10 diagnosis of ADHD (F90.0). * K-ARS scores of 18 or higher for females and 22 or higher for males. * No changes in ADHD medication dosage or regimen within 1 month prior to enrollment (\*For those receiving pharmacological treatment with methylphenidate or amphetamine-based products, a washout period of 14 days is required if they wish to participate after discontinuing medication). * Medically healthy based on medical history and vital signs assessed during screening, without other medical abnormalities. * Able to use a smartphone or tablet PC that meets specified requirements to operate the mobile application without difficulty. * Both the subject and their guardian voluntarily agree to participate and provide written informed consent. Exclusion Criteria: * Subjects will be excluded if they meet any of the following criteria: * Presence of any of the following psychiatric symptoms at baseline: chronic tic disorder (requiring medication), Tourette's disorder, or history of major obsessive-compulsive disorder, schizophrenia, bipolar disorder, post-traumatic stress disorder, conduct disorder, or other childhood psychosis (affective disorders are not exclusionary). * Wechsler Intelligence Scale for Children (WISC) score below 80. * Presence of congenital genetic disorders. * Uncontrolled or severe systemic physical illness requiring hospitalization at baseline. * Suicide attempt within the past 3 months and assessed as high suicide risk by a psychiatrist. * Initiation or ongoing other cognitive behavioral therapy within the past 3 months (including any CBT for ADHD or other conditions, based on insurance coverage). * Presence of visual, auditory, or cognitive impairments. * Any other reasons deemed by the investigator to make the subject unsuitable for participation in the clinical trial.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ADHD are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Emotiv

    Seoul, gangnam, 06179, South Korea

More trials for these conditions

Other studies related to the condition(s) this trial covers.